within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EB11_Aumolertinib;

model Aumolertinib
  extends Pharmacolibrary.Drugs.ATC.L.L01EB11;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01EB11</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Aumolertinib is a third-generation, oral, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC). It is approved in China for the treatment of patients with advanced or metastatic NSCLC harboring EGFR mutations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with advanced NSCLC following oral administration. Population PK analyses and clinical studies support the following estimates.</p><h4>References</h4><ol><li><p>Ji, W, et al., &amp; Zhang, X (2022). Effect of Food Intake on Pharmacokinetics of Oral Almonertinib: A Randomized Crossover Trial in Healthy Chinese Participants. <i>Clinical pharmacology in drug development</i> 11(9) 1046â€“1053. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1095&quot;>10.1002/cpdd.1095</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35437951/&quot;>https://pubmed.ncbi.nlm.nih.gov/35437951</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Aumolertinib;
